Clinical Trial Update: Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 trial update evaluating zanubrutinib in combination with Pola-R-CHP and high-dose methotrexate for secondary central nervous system lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Trexall (Methotrexate)

Snippet

Sponsor: Juan P. Alderuccio, MD | Conditions: CNS Lymphoma | Phase 1 | Status: RECRUITING